Public October 1 event will feature key treatment advances impacting people with breast, lung and prostate cancers New research is changing what we know about breast, lung, and prostate cancers. On Thursday, October 1, the Alliance for Clinical Trials in Oncology will host a public webinar highlighting key findings from Alliance and Alliance Foundation Trials…
The ALCHEMIST Chemo-IO Trial (Alliance A081801) trial, led by Jacob Sands, MD, at Dana-Farber Cancer Institute, together with ALCHEMIST study chair David Kozono, MD, PhD, continues to advance research aimed at improving treatment for patients with resected non-small cell lung cancer (NSCLC). Alliance A081801, part of the ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and…
The media relations efforts from Alliance staff and researchers are designed to alert the public about the vital work happening across our network. When we share stories about clinical trial results, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. More than just news mentions, these media stories serve…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new radiation therapy techniques for lung cancer to treatments for breast cancer side effects, these trials aim to improve outcomes, reduce side effects, and deliver more…
At the Alliance for Clinical Trials in Oncology, our media relations efforts are designed to alert the public about the vital work happening across our network. When we share stories about groundbreaking clinical trials, scientific milestones, or investigator achievements, we are showcasing the real-world progress you help make possible. These media features serve a crucial…
The Alliance for Clinical Trials in Oncology has launched a new national study to see if an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Alliance A082302 aims to enroll 336 participants in this phase III trial specifically focusing on patients with stage I non-small cell lung cancer. Currently, after…
The Alliance for Clinical Trials in Oncology has recently launched several new clinical trials exploring targeted radiation therapy, improved treatment strategies and other innovative approaches to cancer care. From testing new radiation therapy techniques for lung cancer to treatments for breast cancer side effects, these trials aim to improve outcomes, reduce side effects, and deliver more…
At the Alliance for Clinical Trials in Oncology, we love sharing stories that show what’s happening in cancer research right now. Whether it’s a new clinical trial, a scientific breakthrough, or the work of one of our dedicated investigators, we want people to see the progress being made, and the real humans behind it. These…
The Alliance for Clinical Trials in Oncology and Alliance Foundation Trials will present a diverse portfolio of research at the 2026 ASCO Annual Meeting, taking place May 29-June 2 in Chicago, Illinois, spanning breast, gastrointestinal, genitourinary, thoracic, neuro-oncology, health outcomes, and data science. Collectively, these studies reflect the continued leadership of the Alliance in practice-changing clinical trials, translational biomarker…
Recently activated phase II clinical trial will evaluate post‑operative radiation in non-small cell lung cancer The Alliance for Clinical Trials in Oncology has launched a new clinical research study to explore whether a more targeted form of radiation therapy lowers the chance of lung cancer returning after surgery. The study (Alliance A082402) is for people…